ZIVO - Zivo Bioscience, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1030
-0.0020 (-1.90%)
At close: 3:22PM EDT
Stock chart is not supported by your current browser
Previous Close0.1050
Open0.1000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1000 - 0.1030
52 Week Range0.0100 - 0.1900
Volume15,200
Avg. Volume87,531
Market Cap19.795M
Beta (3Y Monthly)0.34
PE Ratio (TTM)N/A
EPS (TTM)-0.0830
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE2 months ago

    ZIVO To Hold Its Annual Meeting May 1, 2019 at the Detroit Athletic Club

    KEEGO HARBOR, MI / ACCESSWIRE / April 29, 2019 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a Michigan-based biotech/agtech R&D company will hold the Annual Meeting of shareholders of Zivo Bioscience, Inc. on ...

  • ACCESSWIRE2 months ago

    Zivo Commences Third Dairy Cow Mastitis Trial to Validate Efficacy and Method of Administration for a New Pathogen Target

    KEEGO HARBOR, MI / ACCESSWIRE / April 8, 2019 / ZIVO Bioscience, Inc. (ZIVO) a Michigan-based biotech/agtech R&D company has commenced a third in vivo dairy cow mastitis study to validate its bioactive compounds in combating a specific infective pathogen via a specific method of administration. The trial is already underway and is being conducted by Dairy Experts, based in Tulare County, California. This research group has worked successfully with the Company in two previous trials, including the landmark study that indicated efficacy of ZIVO bioactives in combatting a drug-resistant pathogen.

  • ACCESSWIRE5 months ago

    Zivo Subsidiary Wellmetrix LLC Announces Milestone Patent

    KEEGO HARBOR, MI / ACCESSWIRE / January 22, 2019 / ZIVO Bioscience, Inc. (ZIVO) subsidiary WellMetrix, LLC presented its latest technology to analysts and investors at the Digital Medicine and Medtech Showcase held during the annual JPMorgan global healthcare conference in San Francisco January 6 - 10, 2019. The conference drew thousands of health industry insiders from around the world. The patent describes the novel use of urinary biomarkers to assess metabolic efficiency and vitality, rather than attempting to use standard medical diagnostics to assess healthiness.

  • ACCESSWIRE6 months ago

    ZIVO Nutritional Efficacy Study for Poultry is Successful, Confirms Production Methods and Health Benefits

    KEEGO HARBOR, MI / ACCESSWIRE / December 19, 2018 / ZIVO Bioscience, Inc. (ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that preliminary data analysis from its most recent poultry nutritional efficacy study show positive results that confirm the successes of previous poultry efficacy studies conducted in partnership with NutriQuest, a global innovator in animal nutrition. The 5,000-bird study, supervised by ZIVO Bioscience and conducted at a Maryland-based contract research organization, confirms that pelleted feed containing ZIVO algal biomass consumed in sufficient quantity results in birds exhibiting improved health indicators. The study further confirms that production and manufacturing methods developed by ZIVO and its research partners provide for a heat-stable, easily-processed feed ingredient that can withstand the pelleting process used in modern poultry feed manufacturing, while maintaining a nutritional profile that supports animal health.

  • ACCESSWIRE7 months ago

    Zivo Bioscience Executes Letter Of Intent With Dr. Steven K. Grekin/Grekin Laboratories To Field Exclusive Line Of Beauty-From-Within Nutraceuticals

    KEEGO HARBOR, MI / ACCESSWIRE / December 3, 2018 / ZIVO Bioscience, Inc. (ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that company principals have executed a letter of intent with Dr. Steven K. Grekin, an innovator and pioneer in dermatological practices focused on anti-aging and skin health. The letter of intent describes a joint effort to develop, test and launch an exclusive line of products that feature the Company's proprietary algae strain, which has recently been affirmed Generally Recognized As Safe (GRAS). This recent development allows ZIVO to immediately engage in product development and sales – in this instance, a line of nutritional products developed for Dr. Grekin.

  • ACCESSWIRE7 months ago

    Zivo Claims Gras Status for its Proprietary Algal Biomass, Allowing Immediate Marketing of its Premiere Product as a Human Food Ingredient

    KEEGO HARBOR, MI / ACCESSWIRE / November 12, 2018 / ZIVO Bioscience, Inc. (ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that it has received notice from an independent scientific review panel that ZIVO has satisfied the safety and process requirements to affirm GRAS status for its proprietary Kalgae™ branded dried algal biomass. GRAS refers to FDA designation Generally Recognized As Safe and allows the Company to market its product as an ingredient in a defined range of foods and beverages. Initially, the Company will target vegan and functional food & beverage categories, ranging from veggie smoothies to snack bars intended for human consumption.

  • ACCESSWIRE8 months ago

    ZIVO Bioscience, Inc. Annual Shareholder Meeting and Conference Call Slated for November 7, 2018 in Detroit, Michigan

    KEEGO HARBOR, MI / ACCESSWIRE / October 30, 2018 / ZIVO Bioscience, Inc., (OTCQB: ZIVO ) a Michigan-based biotech firm, invites shareholders, analysts and partners to its annual shareholder meeting on ...

  • ACCESSWIRE9 months ago

    Zivo Safety Study Accepted for Publication in Toxicology Journal, Allows Company to Proceed with GRAS Review Panel for Market Approval

    KEEGO HARBOR, MI / ACCESSWIRE / September 20, 2018 / ZIVO Bioscience, Inc. (ZIVO) abiotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that Toxicology Reports, a peer-reviewed scientific journal, has accepted the Company's safety testing manuscript for publication. This is a necessary step in meeting compliance requirements for GRAS (Generally Recognized As Safe) affirmation and subsequent market entry.With the acceptance in hand, ZIVO can now move forward with a GRAS science panel review, the last regulatory step before ZIVO can commence sale of its algal biomass as a human food ingredient. The GRAS science panel is composed of food safety and food science academics and industry specialists.

  • ACCESSWIRElast year

    Food & Beverage/Consumer Packaged Goods Industry Veteran Joins ZIVO Bioscience, Inc. as VP - Global Operations

    KEEGO HARBOR, MI / ACCESSWIRE / June 21, 2018 / ZIVO Bioscience, Inc. (ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from its proprietary algal strains, announces today that Ronald C. Costephens has joined the Company as Vice-President- Global Operations. Mr. Costephens is charged with building out a global supply chain and an organization to help transition ZIVO from an R&D entity into an operating enterprise that will engage not only in the licensing of its intellectual property portfolio, but also in handling the production and distribution of bulk and finished food, beverage and feed products featuring its proprietary algal strains. Mr. Costephens brings more than 30 years of leadership experience in the Consumer Packaged Goods (CPG) global industry in Engineering, Business Development, Operations and Procurement to his role as Vice-President, Global Operations at ZIVO Bioscience, Inc. His successful career operating in global markets includes both Fortune 50 and private organizations.